Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 89, Issue 3, 2010, Pages 216-223

  Kikuchi, Masatoshi ^a   Haneda, Masakazu ^b   Koya, Daisuke ^c   Tobe, Kazuyuki ^d   Onishi, Yukiko ^a   Couturier, Andre ^e   Mimori, Nobuyuki ^f   Inaba, Yoko ^f   Goodman, Matthew ^g  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY   (Japan)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS PHARMA K K   (Japan)

^g Research Centre   (United Kingdom)

Author keywords

Dipeptidyl peptidase 4; Glimepiride; Vildagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA AMYLASE PANCREAS ISOENZYME; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; PHOSPHOTRANSFERASE; PLACEBO; POTASSIUM; VILDAGLIPTIN;

ACUTE PYELONEPHRITIS; ADD ON THERAPY; ADULT; AGED; ARTICLE; ASTHENIA; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HUNGER; HYPERHIDROSIS; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; TREMOR;

EID: 77955428835     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.04.017     Document Type: Article

References (29)

1. International Diabetes Federation. Diabetes atlas: executive summary third edition (online). Available from URL: (accessed 2008 June 17). http://www.eatlas.idf.org/.
2. Kawamori R. Diabetes trends in Japan. Diabetes Metab. Res. Rev. 2002, 18(S3):S9-S13.
3. Hirose T., Kawamori R. Diabetes in Japan. Curr. Diab. Rep. 2005, 5(3):226-229.
4. Brown J.B., Nichols G.A., Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004, 27:1535-1540.
5. Koro C.E., Bowlin S.J., Bourgeois N., Fedder D.O. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004, 27:17-20.
6. Saydah S., Cowie C., Eberhardt M.S., De Rekeneire N., Narayan K.M. Race and ethnic differences in glycemic control among adults with diagnosed diabetes in the United States. Ethn. Dis. 2007, 17:529-535.
7. Krentz A.J., Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 3:385-411.
8. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
9. Turner R.C., Cull C.A., Frighi V., Holmann R.R. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012.
10. Ahrén B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:2078-2084.
11. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Saylan M., Dunning B.E., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2005, 90:4888-4894.
12. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., et al. 1-[[(3-Hydroxy-1-damantly)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003, 46:2774-2789.
13. Balas B., Baig M.R., Watson C., Dunning B.E., Ligueros-Saylan M., Wang Y., et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2007, 92:1249-1255.
14. Pi-Sunyer F.X., Schweizer A., Mills D., Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2007, 76:132-138.
15. Dejager S., Razac S., Foley J.E., Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multipledose study. Horm. Metab. Res. 2007, 39:218-223.
16. Bosi E., Camisasca R.P., Collober C., Rochotte E., Garber A.J. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30:890-893.
17. Ahrén B., Gomis R., Standl E., Mills D., Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880.
18. Garber A.J., Schweizer A., Baron M.A., Rochotte E., Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo controlled study. Diabetes Obes. Metab. 2007, 9:166-174.
19. Garber A.J., Foley J.E., Banerji M.A., Ebling P., Gudbjörnsdottir S., Camisasca R.P., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 2008, 11:1047-1056.
20. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
21. Kikuchi M., Abe N., Kato M., Terao S., Mimori N., Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2009, 83:233-240.
22. Idris I., Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes. Metab. 2007, 9:153-165.
23. Del Prato S., Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006, 55:S20-S27.
24. Japan Diabetes Society Treatment objective and index for blood glucose control. Guidance for diabetes therapy 2006-2007 2006, Japan Diabetes Society, Bunkodo, Tokyo.
25. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003, 26(S1):S33-S50.
26. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. 2007, 9:733-745.
27. Holman R.R., Cull C.A., Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999, 22:960-964.
28. Hirose T., Miyashita Y., Takagi M. Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea. Diabetes Res. Clin. Pract. 2001, 54:9-15.
29. Hayashi Y., Miyachi N., Takeuchi T. Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile. Diabetes Obes. Metab. 2003, 5:58-65.